Sharemaestro Newsreel

Liquidia Corp (LQDA) Valuation: PE, PB & Fair Value Analysis

Liquidia Corp (LQDA) currently holds a valuation score of 6.12, placing it 146th out of 155 companies in the Pharmaceuticals industry. Its P/E ratio is 346.96, which is slightly below its recent high and significantly above its recent low. The company has not yet …

Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Lifecore Biomedical Inc (LFCR), a company within the Pharmaceuticals industry. It highlights that LFCR has a risk assessment score of 4.90, ranking 78 out of 155 in its industry, and a beta value of 1.07. The report …

INDV|Indivior PLC|Price:40.970|Chg%:+0.940

This article provides a comprehensive stock analysis of Indivior PLC (INDV) by TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. The analysis details Indivior's score, key insights, and an overview of its product portfolio for substance-use …

LNTH|Lantheus Holdings Inc|Price:102.540|Chg%:-5.490

This article provides a comprehensive stock analysis of Lantheus Holdings Inc (LNTH) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. Despite recent weak market performance, the company exhibits robust fundamentals and is considered …

ANIP|ANI Pharmaceuticals Inc|Price:79.255|Chg%:-1.175

This article provides a comprehensive stock analysis of ANI Pharmaceuticals Inc (ANIP) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The analysis also covers institutional ownership, analyst ratings, and a detailed breakdown of how …

Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence

Amylyx Pharmaceuticals Inc (AMLX) has an institutional shareholding score of 10.00, placing it at the top of the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 5.01% quarter-over-quarter, reaching 104.12%. Fidelity Management & Research Company LLC is a significant institutional shareholder, increasing …

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aquestive Therapeutics Inc (AQST), highlighting its current price momentum score, support and resistance levels, and indicator readings. It details various technical indicators like MACD, RSI, and moving averages, offering "Sell", "Neutral", and "Buy" signals. The analysis suggests …

ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership significantly increased its stake in ANI Pharmaceuticals (ANIP) by 19.3% in the first quarter, now owning 2.52% of the company's shares. This comes as ANI Pharmaceuticals reported strong quarterly results, exceeding EPS and revenue consensus estimates, and provided positive fiscal …

ANI Pharmaceuticals Inc (ANIP) Institutional Confidence

ANI Pharmaceuticals Inc (ANIP) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 101.74%, showing a 1.25% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.87% of shares outstanding.

Renaissance Technologies LLC Acquires 31,435 Shares of Phibro Animal Health Corporation $PAHC

Lantheus (LNTH) to Release Earnings on Wednesday

HC Wainwright Analysts Decrease Earnings Estimates for CRDL

Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday

Cumberland Pharmaceuticals (CPIX.US) will release its earnings report after the market closes on August 4.

Perrigo (PRGO) Projected to Release Quarterly Earnings on Wednesday

Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday

Anika Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIK) 2026-07-29

Aurora Cannabis (ACB) to Post Quarterly Earnings on Wednesday

Phibro Animal Health Corporation (NASDAQ:PAHC) Announces $0.12 Quarterly Dividend

BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday

Wedbush Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD

Amneal Pharmaceuticals stock (AMRX) recently hit a 52-week high of $18.59, reflecting a 123.61% increase over the past year. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q1 2026 results and received FDA approvals for …

Tilray Brands, Inc. Stock 12‑Month Price Target Cut to $8.52, Implies 111% Upside

Tilray Brands, Inc.'s average 12-month price target has been cut to $8.52 from $8.62, according to estimates from 6 analysts. This updated target implies a potential upside of approximately 111% from its July 28 closing price. The consensus rating for TLRY remains "Buy," with …

Indivior PLC (INDV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Indivior PLC (INDV), highlighting its current risk score of 6.43, ranking 53 out of 155 in the Pharmaceuticals industry. The company's beta of 1.18 suggests it tends to outperform during market uptrends but underperform during downtrends. The …

Bausch Health Companies Inc (BHC) Valuation: PE, PB & Fair Value Analysis

Bausch Health Companies Inc (BHC) has a current valuation score of 9.34, ranking 27th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio is -1.40, which is significantly below its recent high and above its recent low. However, relevant data for …

TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA

This article provides a revenue breakdown for TherapeuticsMD, Inc. (SWB:29TA), highlighting that the greatest contribution to its revenue comes from the United States. The company reported €1.53 million from the U.S. last year, an increase from €1.08 million the year prior. The data is …

Supernus Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Supernus Pharmaceuticals (NASDAQ: SUPN) had 793 employees as of March 2026, representing a 25.8% decline from 2023. The company is actively hiring, with 105 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, …

Evotec SE (EVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evotec SE (EVO), focusing on its current price momentum, support and resistance levels, and key indicators like MACD, RSI, and Moving Averages. The stock's price momentum score is 5.21, and it is trading between a resistance of …

Tilray Brands 4Q Loss/Shr 43c >TLRY

Tilray Brands reported a fourth-quarter loss per share of 43 cents. This financial update indicates the company's performance for the recent quarter.

Tilray Brands Inc reports results for the quarter ended May 31 - Earnings Summary

Tilray Brands Inc has released its earnings summary for the quarter that concluded on May 31. The report contains the financial results for the company during this period. The full article provides detailed information on their performance.

Sonoma Pharmaceuticals (Nasdaq: SNOA) 2026 pay, board and auditor votes

Sonoma Pharmaceuticals (SNOA) has issued its definitive proxy statement for the 2026 Annual Meeting, scheduled for September 16, 2026. Shareholders will vote on the re-election of Class III director Jerry McLaughlin, an advisory approval of executive compensation for fiscal year 2026, and the ratification …

Dr. Reddy’s Laboratories (NYSE: RDY) details Q1 impact from semaglutide

Dr. Reddy's Laboratories reported a 5.6% year-on-year decline in Q1 FY27 consolidated revenues, totaling ₹8,071 crores, primarily due to lower lenalidomide sales and a ₹240 crore provision for semaglutide API issues. Despite this, the base business, excluding lenalidomide, showed healthy double-digit growth across key …

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis

Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.50, placing it 50th out of 155 companies in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 42.25% to $814.50 million and …